To examine potential effects of cancer treatment resistance on BA sensitivity, we established A549 cells resistant to osimertinib, a tyrosine kinase inhibitor (TKI) for the epidermal growth factor receptor (EGFR) administered for the treatment of NSCLC. The gene discussed is EGFR; the disease is cancer.